Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04754399 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT04754399 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 40 participants.
The verdict
NCT04754399, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Study of Cannabidol to examine the safety and efficacy of 15 weeks of CBD in postmenopausal women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Investigators are looking to see if patients with joint pain see improvement with the use of CBD.
Interventions
- DRUG Cannabidiol (CBD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-04-16 |
| Est. Completion | 2023-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04754399
The ClinicalTrials.gov registry entry for NCT04754399 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cannabidiol (CBD) is the first listed.
NCT04754399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04754399 about?
NCT04754399 is a clinical study titled "Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias". Study of Cannabidol to examine the safety and efficacy of 15 weeks of CBD in postmenopausal women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Investigators are looking to see if patients with joint pain see improvement with the use of CBD.
What is the current status of trial NCT04754399?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-04-16. Estimated completion is 2023-10-10.
What interventions are being tested in trial NCT04754399?
The interventions under investigation include: Cannabidiol (CBD) (DRUG).
Who is sponsoring clinical trial NCT04754399?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.